Delanzomib

Drug Profile

Delanzomib

Alternative Names: CEP-18770; CIP 18770; CT-18770; CT-47098; E/CEP-18770; NP-47098; NPH007098

Latest Information Update: 24 Sep 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cephalon
  • Developer Cephalon; EOS S.p.A.; Teva Pharmaceutical Industries
  • Class Amino acids peptides and proteins; Antineoplastics; Boronic acids; Peptidomimetics; Small molecules
  • Mechanism of Action Apoptosis stimulants; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma; Solid tumours
  • No development reported Systemic lupus erythematosus
  • Discontinued Multiple myeloma

Most Recent Events

  • 24 Sep 2013 No development reported - Preclinical for Systemic lupus erythematosus in USA (IV)
  • 10 May 2013 Discontinued - Phase-II for Multiple myeloma (second-line therapy or greater) in USA and Spain (IV)
  • 01 May 2013 Discontinued - Phase-I/II for Multiple myeloma (combination therapy, second-line therapy or greater) in New Zealand and USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top